# Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail

> **Open Intelligence Dossier** · First detected: 2026-10-28 10:40 UTC · Category: Business

## Executive Summary
Novartis faces a multi-billion dollar financial hit from clinical trial setbacks yet maintains financial guidance.

## Intelligence Brief
Recent business reporting details a significant financial and clinical development involving pharmaceutical company Novartis. According to coverage from outlets including BioSpace, the Wall Street Journal, Fierce Pharma, the Financial Times, FirstWord Pharma, Reuters, and Fierce Biotech, Novartis is managing a $1.9 billion hit tied to the failure of the drug del-desiran. Additional reporting from Reuters notes a broader total financial impact of $2.2 billion stemming from various drug trial setbacks. Despite these substantial write-downs and trial failures, the leadership at Novartis has expressed continued confidence in its broader corporate strategy, specifically maintaining faith in a twelve billion dollar acquisition involving Avidity. Media coverage heavily emphasizes the resilience of the company&amp;#039;s executive leadership in the face of these high-profile clinical failures.


The Financial Times and Fierce Pharma highlight that the chief executive officer remains unfazed by the setbacks, keeping long-term revenue goals intact. Simultaneously, financial reporting from the Wall Street Journal, FirstWord Pharma, and Reuters points out that Novartis has chosen to raise its annual profit guidance. This juxtaposition of substantial drug trial writedowns alongside lifted financial guidance forms the primary focus of the business reporting across all seven tracked news sources. This unfolding situation builds upon prior corporate actions and major financial investments by Novartis, most notably the blockbusting twelve billion dollar acquisition of Avidity. The recent clinical failure of del-desiran represents a major hurdle following that acquisition, testing the pharmaceutical firm&amp;#039;s broader pipeline and financial resilience.


Coverage does not yet specify the exact operational steps researchers will take next regarding the failed drug, but the current reporting establishes that the company&amp;#039;s long-term financial planning remains anchored despite the immediate losses. Observers and market analysts will be tracking subsequent corporate announcements to monitor how Novartis navigates its updated profit guidance and integrates its major acquisitions following these trials. While current headlines establish the immediate financial hits and leadership responses, future coverage will likely determine the longer-term market repercussions of the del-desiran setback. Readers should consult ongoing financial reports for updates on how the company manages its remaining portfolio in light of these multi-billion dollar adjustments.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| BioSpace | Novartis faces $1.9B hit from Avidity fail but maintains confidence in $12B buy | [Source Link](https://news.google.com/rss/articles/CBMisAFBVV95cUxNOHM4bGdqeXVhVnJaMjBmSEdXMlo2ODJYU3RiT2RfRURldGo2ejFnajJLejE3SHJXZmdNclJwQllHdVZuTmNmOTM0U3AybzI4ZEs1R3VHamZ3WEtnMkF6bGRUVFpKUUxWdHNJQjN6M2lOdWNlbWFtS0RpUW9EQ3Z4QXlxcWYtc19BSnpVSE9SdzhXU1hDZHVWMTVCTzVnWmYwYWN1Y2lrSVY4dC12S0JXSQ?oc=5) |
| WSJ | Novartis Raises Guidance Despite Drug-Trial Setbacks Hitting Profit | [Source Link](https://news.google.com/rss/articles/CBMirgFBVV95cUxOaVFMeFV6aEp4TlZ0cGg2SVBPSVoxTlp5cnlFLTl5TU16QUtBeXNfcFFMelg3QUg2WVkwdmFpbXpqNDZYcmJxNWFJcFhNRU90MWhSdzZNejFNeVVTd21ZeHZKZnk2SU5OZWhURXpmVHpkWXJ4V01iRDh6MnBKQ1RXb2JTSjhOVmFURVF6ejlYcURla2NLUl9rcnNRMmdyVGlndlRBSTZweWpuTmU5Nmc?oc=5) |
| Fierce Pharma | Novartis CEO unfazed by high-profile clinical failures, maintains long-term revenue goal | [Source Link](https://news.google.com/rss/articles/CBMivAFBVV95cUxQRkRaVUs2ME9YWGhWTXpPZTFhVS10djhocGhXbmU4Yk9hQ0dpb255Q0wzOFQwTEJaTXZMcUlPam1qcVFodzZXSXk0TlhlbTF2ZjdHcjItWlJBcEpOTTBvWkZNektWUkotb1NEbV9aNlU3bnpZUGVOeDlpbjRVX2p0ZGdJWkVMWE9FUXlDRlJPZzdEWWZyZ0NrYjQ2RG02REUzOEprNGRUbVlvRmlscXhuV1F3M2R6MWpVX2pBdw?oc=5) |
| Financial Times | Novartis takes $1.9bn writedown on key drug after blockbuster Avidity acquisition | [Source Link](https://news.google.com/rss/articles/CBMihAFBVV95cUxPb0JTOEdkUGhfaWJVUGxDb2RUWW1QRS1ieTY2YWdEbjktOUs5STFsOHVIbVVpbGVrc01MX0I0aTEybzRrNEswbmdOYkYwZ3lCNnpfTEQ2Zzh4aFFaN1czVUlxWldqRkVidTRmMW5GY3NOYWJTN1RQb2p1WHVWVzRzU0pCazE?oc=5) |
| FirstWord Pharma | Novartis lifts annual profit guidance despite $1.9B hit from del-desiran failure | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTE0xVWdxRXVXcXZTMjdQeTBrSDZLczZKV3Fkam1YSWlyS1JYcHJWNmh3WHFfcHNMR2h3ak9PU2pxVWVCOG5FRFExTW85aWRfVW5FRkpz?oc=5) |
| Reuters | Novartis books $2.2 billion hit from drug trial setbacks, but lifts guidance | [Source Link](https://news.google.com/rss/articles/CBMixwFBVV95cUxORGNqcHZHNndLNXNGbW1HaUNsU2tDUm9aS3pLNFYtRGZPckNKbEgxcVlVRDN4QmF2dDQ4YlVZa05FRzBlcGtvNkF5Y191Vzc2cE5VaHlfMEFoLWt2RFBNc0RvUHNTQlZQQlJhR21TUEhNQXJXZlEyTUNhUXd0S1BwUWRhNG51dVpCSERJV1Rab0N0S0pFV3V5RUFRNmd6RzNuWWVGTVZKRjJaaUpSYXlPNFlzZm12YTQyWDNCWng1UUpYR3hVYlUw?oc=5) |
| Fierce Biotech | Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail | [Source Link](https://news.google.com/rss/articles/CBMirAFBVV95cUxPMnNYTTVJcHEybndQTlVRLVhCVzBQT0JLZER1cFhPTnVaRFVDQlhsWU9sLXloNDFNTk1YekstOTFjTnRFdzREQ1h6RUZZOE9XZTd3TUJDNlhtcE9wVFJ1VWs2NTZiUC1aNlhQLXF6SlF2QjJMamgtT3NkbmdLbmhIZW9Md2tlSHZoWTV3Y3NTbW96Q0NuU3hRTUpBLURDbkpTU1U5TGlTRmlOLW9a?oc=5) |

---
*Canonical Source: https://pulse.byoaiapps.com/trend/2026-10-28/novartis-ceo-keeps-faith-in-avidity-deal-despite-taking-1-9b-hit-from-del*
